Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force.This enables myosins to generate tension on actin filaments, which in turn allows them to walk along these filaments and propel the sliding of actin filaments. Myosins are able to control the cytoskeleton's dynamics and structure, which has an impact on how cells are transported and localized. According to their respective motor domains, the various myosins are divided into classes. Humans have 40 myosin genes, which are divided into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX, and XXXV) and represent the 35 known classes of myosin.
Muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organization, and cell signaling are just a few of the critical processes that myosins participate in. Deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome, and cancer have all been linked to myosin dysfunction.
In order to perform its role in cytoskeleton contraction and tight junction regulation, the myosin light chain needs to be activated by the enzyme myosin light chain kinase (MLCK). In the majority of cells, MLCK functions as a signal transducer for MLC phosphorylation in response to Ca2+ binding to calmodulin associated with MLCK. Muscle contraction, cell migration, and endo/exocytic processes all benefit from MLCK-mediated MLC phosphorylation and actomyosin contractility, which is also known for playing a crucial part in signaling endothelial cell-cell adhesion and barrier function.
|16-38-Thymosin β4 (cattle)
|16-38-Thymosin β4 (cattle) (TFA)
|BTS is a novel and potent inhibitor of ATPase activity of skeletal muscle myosin II subfragment 1 (S1),specifically theCa2+-stimulated myosin S1 ATPase (IC50 = 5 μM).
|ML-7 hydrochloride hydrate
|ML-7 (ML7)hydrochloride hydrateis a naphthalene sulphonamide-based MLCK/Myosin light chain kinase inhibitor with anticancer activity.
|Myosin Light Chain Kinase Substrate (smooth muscle)
|Omecamtiv mecarbil (CK1827452)
|Omecamtiv mecarbil (also known as CK-1827452) is a specific/selective cardiac myosin activator and a clinical drug for left ventricular systolic heart failure.
|Omecamtiv mecarbil-d8 (CK-1827452-d8)